Praxis Precision Medicines, a clinical-stage genetic neuroscience company, that develops therapies for complex and debilitating brain disorders, announced that it has raised anoter $110 Million to advance its ion channel drugs for the treatment of neurological disorders.
Praxis has now 3 clinical-stage assets: PRAX-114, a GABAA positive allosteric modulator, currently in Phase 2 development for the treatment of major depressive disorder and perimenopausal depression; PRAX-944, a T-type calcium channel blocker, currently in Phase 2 development for the treatment of essential tremor; and PRAX-562, currently in Phase 1 development for the treatment of pediatric epilepsy and adult cephalgia.
Other treatments, PRAX-020/021 and PRAX-222, are in preclinical development for genetic epilepsies.
Image by Ahmed Gad from Pixabay
